PGR and cancer: Additionally, ER + progesterone receptors (PR) + cancer cells were used to evaluate the anticancer effects of EGCG by epigenetic downregulation of ER- through p38 mitogen-activated protein kinase(p38MAPK)/casein kinase 2 (CK2) activation [107].